Ace the Case: Older Adult with Therapy-Related AML is organized by Healio, American Academy of CME, Inc..
Release date: February 23, 2023
Expiration date: February 23, 2024
Activity Description:
Knowledge of the key management issues for patients with AML is critical Patients receiving both standard chemotherapy and newer agents need to be monitored for, and educated about, the risk of infection, bleeding and potential adverse events associated with treatment. Early identification and intervention are critical to reduce the potential for serious adverse events and complications.
Key questions to be addressed within this activity include:
What are the available approved agents for patients with newly diagnosed and relapsed AML and their implications for patient selection, and clinical care?
How does the clinical care team evaluate patients with AML receiving treatment with recently approved agents to identify early indications of adverse events and implement appropriate interventions?
What should the care team outline for the patient and family/caregiver to prevent infection, identify signs of bleeding, and perform other assessments to improve early identification and management of adverse events?
Learning Objectives:
After participating in the activity, learners should be better able to:
- Identify and recognize key molecular and cytogenetic markers and their impact on the prognosis of a patient with AML
- Review and appraise recently approved targeted agents for patients with newly diagnosed and relapsed AML and their place in therapy
- Identify key warnings and adverse drug reactions associated with new therapies and select an appropriate multidisciplinary management strategy
- Consider challenges with your care team to treating patients during the COVID-19 pandemic and measures that can be implemented to reduce patients’ risk of infection while upholding evidence-based medicine